Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.35 |
| ▸ | GRM5 | P41594 | 8/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655993 | 0.87 | GRM1 (0.36) | NR1H2GRM1GRM5ESR2PDK4 | |
| SCHEMBL29045081 | 0.80 | NR1H2 (0.42) | NR1H2GRM1GRM5ESR2PDK4 | |
| SCHEMBL15390474 | 0.80 | NR1H2 (0.39) | NR1H2GRM1GRM5ESR2PDK4 | |
| SCHEMBL29135458 | 0.80 | GRM1 (0.34) | NR1H2GRM1GRM5ESR2PDK4 | |
| SCHEMBL8120965 | 0.80 | ESR2 (0.38) | NR1H2GRM1GRM5ESR2PDK4 | |
| SCHEMBL10081639 | 0.77 | POLB (0.37) | NR1H2GRM1GRM5ESR2PDK4 | |
| Hydrazine SCHEMBL29123108 | 0.77 | GRM1 (0.35) | NR1H2GRM1GRM5ESR2PDK4 | |
| SCHEMBL28303569 | 0.76 | KEAP1 (0.34) | — | |
| SCHEMBL29045102 | 0.76 | NR1H2 (0.36) | NR1H2GRM1GRM5DPP4 | |
| SCHEMBL27486896 | 0.76 | ACHE (0.42) | NR1H2GRM1GRM5SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314217-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7871997-B2 | Cephalosporin compounds | THERAVANCE, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1633759-B1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080103299-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2008-05-01 | — | — | US | disclosed |
| US-7332471-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7067481-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060128612-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-06-15 | — | — | US | disclosed |
| EP-1633759-A1 | CROSS-LINKED GLYCOPEPTIDE - CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-12-30 | — | — | US | disclosed |
| WO-2004113350-A1 | CROSS-LINKED GLYCOPEPTIDE - CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | GYPA, CSGALNACT1, ST3GAL3 | NR1H2 3908/4885GRM1 2465/4885GRM5 2496/4885 |
| US-20060128612-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | NR1H2 4050/4885GRM1 2763/4885GRM5 2625/4885 |
| US-20080103299-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | NR1H2 4009/4885GRM1 2838/4885GRM5 2677/4885 |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | NR1H2 4009/4885GRM1 2838/4885GRM5 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.